Proteomics International is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins.
Proteomics International’s aim is to use its expertise in proteins to develop and commercialise diagnostic tests for chronic diseases where there is unmet medical need.
To maximise shareholder value in a financially sustainable manner, PI’s strategy is to:
PI is executing a stepped rollout of its flagship diagnostic test for diabetic kidney disease. Successful commercialisation of PromarkerD provides the opportunity to enjoy ongoing returns through licensing fees and royalty payments, which will grow as the test is adopted by more physicians and licensed into new geographic regions.
PI is continuing to research potential diagnostic tests for endometriosis and Giardia, developing a pipeline of diagnostic tests which can be commercialised after PromarkerD. As these tests are commercialised, they will increase long-term revenue via licensing fees and royalty payments.
The company’s Analytical Services provide fee-for-service revenue. This contributes to financially supporting the company’s commercialisation and research activities, until they start to pay dividends. They also offer synergies in access to markets and clients.
Proteomics International was established in 2001, and is now recognised as a global leader in the field of proteomics. It operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.
Proteomics is the large-scale mapping of the structure and function of proteins.